Gradient Investments LLC Boosts Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Gradient Investments LLC lifted its stake in shares of DexCom, Inc. (NASDAQ:DXCMGet Rating) by 329.4% during the second quarter, Holdings Channel reports. The fund owned 131,448 shares of the medical device company’s stock after acquiring an additional 100,834 shares during the period. Gradient Investments LLC’s holdings in DexCom were worth $9,797,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Jennison Associates LLC grew its stake in shares of DexCom by 83.4% during the first quarter. Jennison Associates LLC now owns 2,600,283 shares of the medical device company’s stock worth $1,330,305,000 after purchasing an additional 1,182,632 shares in the last quarter. Sands Capital Management LLC grew its stake in shares of DexCom by 33.9% during the first quarter. Sands Capital Management LLC now owns 4,189,245 shares of the medical device company’s stock worth $2,143,218,000 after purchasing an additional 1,060,655 shares in the last quarter. Clearbridge Investments LLC grew its stake in shares of DexCom by 304.3% during the first quarter. Clearbridge Investments LLC now owns 1,318,079 shares of the medical device company’s stock worth $674,329,000 after purchasing an additional 992,049 shares in the last quarter. Capital Research Global Investors grew its stake in shares of DexCom by 55.2% during the fourth quarter. Capital Research Global Investors now owns 2,374,545 shares of the medical device company’s stock worth $1,275,020,000 after purchasing an additional 844,916 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of DexCom during the fourth quarter worth $410,670,000. Hedge funds and other institutional investors own 92.34% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on DXCM shares. Morgan Stanley lowered their target price on shares of DexCom from $91.00 to $83.00 and set an “equal weight” rating for the company in a research note on Friday, July 29th. Wells Fargo & Company decreased their price objective on shares of DexCom from $144.00 to $102.00 in a research note on Friday, July 29th. Robert W. Baird decreased their price objective on shares of DexCom from $115.00 to $97.00 in a research note on Friday, July 29th. BTIG Research decreased their price objective on shares of DexCom from $135.00 to $105.00 and set a “buy” rating for the company in a research note on Friday, June 24th. Finally, Citigroup decreased their price objective on shares of DexCom from $105.00 to $100.00 in a research note on Friday, July 29th. Two research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $115.23.

Insider Buying and Selling

In related news, Director Steven Robert Pacelli sold 1,000 shares of the stock in a transaction dated Tuesday, August 23rd. The shares were sold at an average price of $84.21, for a total transaction of $84,210.00. Following the completion of the transaction, the director now directly owns 137,700 shares of the company’s stock, valued at $11,595,717. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 3,000 shares of company stock valued at $239,830 over the last ninety days. Corporate insiders own 0.41% of the company’s stock.

DexCom Trading Down 1.0 %

NASDAQ DXCM opened at $90.09 on Monday. The stock has a market capitalization of $35.37 billion, a P/E ratio of 187.69, a P/E/G ratio of 3.64 and a beta of 1.03. DexCom, Inc. has a 52-week low of $66.89 and a 52-week high of $164.86. The firm has a 50-day moving average price of $85.55 and a 200 day moving average price of $91.86. The company has a quick ratio of 4.30, a current ratio of 4.72 and a debt-to-equity ratio of 0.87.

DexCom (NASDAQ:DXCMGet Rating) last posted its quarterly earnings results on Thursday, July 28th. The medical device company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.02). The firm had revenue of $696.20 million for the quarter, compared to analysts’ expectations of $709.33 million. DexCom had a return on equity of 11.79% and a net margin of 7.47%. The company’s revenue for the quarter was up 17.0% on a year-over-year basis. During the same period in the prior year, the company earned $0.19 earnings per share. Equities research analysts expect that DexCom, Inc. will post 0.79 EPS for the current year.

About DexCom

(Get Rating)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system.

Featured Articles

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCMGet Rating).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.